Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ailamide
- Development stage
- Unknown
- Lead developer
- Senju Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
**Ailamide** is a Japanese fixed-dose ophthalmic suspension containing brimonidine tartrate 0.1% and brinzolamide 1%. It is marketed for reducing elevated intraocular pressure in glaucoma and ocular hypertension when other glaucoma therapies provide insufficient control. Brimonidine is an alpha-2 adrenergic receptor agonist that reduces aqueous-humor production and promotes uveoscleral outflow, while brinzolamide inhibits carbonic anhydrase II to reduce aqueous-humor secretion. The product was approved in Japan in March 2020 and launched in June 2020 by Senju Pharmaceutical with Otsuka Pharmaceutical as its alliance partner. ([otsuka.co.jp](https://www.otsuka.co.jp/en/company/newsreleases/2020/20200616_1.html))
- Brand names
- Ailamide
- Other names
- 0.1% brimonidine tartrate + 1% brinzolamide fixed-combination ophthalmic suspensionAILAMIDE Combination Ophthalmic Suspensionアイラミド配合懸濁性点眼液
02
Targets
CA2 (Carbonic Anhydrase 2)ADRA2A (α2A)ADRA2B (α2B)ADRA2C (α2C)
Beyond the preview
Go deeper on Ailamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ailamide.